Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cash and cameras: a new way to beat latent TB?

NCT ID NCT05022862

Disease control Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether offering small financial rewards and using video calls to watch people take their medicine can help more people complete treatment for latent tuberculosis. About 399 adults in Baltimore will be randomly assigned to usual care, video check-ins alone, or video check-ins plus incentives. The goal is to see if these strategies boost treatment completion rates and prevent active TB.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
financial incentives and video directly observed therapy (vDOT)
What this could lead to
If successful, this approach could significantly increase the number of people who finish latent TB treatment, reducing the risk of developing active TB and spreading it to others.
What could go wrong
This is a behavioral intervention study, not a drug trial. Results depend on participant motivation and may not apply to other settings. The study is still recruiting, so outcomes are not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 399 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2022

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years old or older, * diagnosed with latent TB and determined to be appropriate for latent TB treatment by participants clinicians * reside in Baltimore metro area * speaks English or Spanish, or a language for which there is a short form available via the Johns Hopkins Medicine Institutional Review Board * prescribed 3 months Isoniazid/Rifapentine, prescribed 3 months Isoniazid/Rifampin, or 4 months Rifampin Exclusion Criteria: * younger than 18 years old * diagnosed with active TB * prescribed an alternative treatment regimen for latent TB * pregnant women (as determined by non-study directed clinical evaluation; BCHD performs urine pregnancy testing on women of child bearing age when indicated) * participant's spoken language does not have a translated long or short consent form

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Latent tuberculosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

latent tuberculosis infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Latent tuberculosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Baltimore City Health Department, and Baltimore metropolitan area clinics and health departments

    RECRUITING

    Baltimore, Maryland, 21205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.